SCHEMBL285992

SCHEMBL285992

CCOC(=O)c1cnc(C=Cc2c(-c3ccccc3)noc2C)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1F O60840 1/20 0.47
CACNA1D Q01668 1/20 0.47
CACNA1S Q13698 1/20 0.47
CACNA1C Q13936 1/20 0.47
ALDH1A1 P00352 4/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PTBP1 P26599 1/20 0.46
GABRA5 P31644 1/20 0.46
CDC7 O00311 2/20 0.44
DBF4 Q9UBU7 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
HDAC6 Q9UBN7 3/20 0.43
HDAC1 Q13547 1/20 0.43
MAPK1 P28482 2/20 0.43
POLB P06746 2/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285991 1.00 CACNA1F (0.47) CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1
SCHEMBL286104 0.90 POLB (0.44) CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1
SCHEMBL286234 0.87 HDAC6 (0.45) LMNASMN1; SMN2GABRA5L3MBTL1HDAC6
SCHEMBL286233 0.87 HDAC6 (0.45) LMNASMN1; SMN2GABRA5L3MBTL1HDAC6
SCHEMBL285892 0.83 KMT2A (0.41) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL2749575 0.83 HDAC6 (0.48) ALDH1A1GABRA5L3MBTL1HDAC6HDAC1
SCHEMBL2749573 0.82 GABRA5 (0.48) ALDH1A1LMNASMN1; SMN2GABRA5L3MBTL1
SCHEMBL285730 0.82 GABRA5 (0.48) ALDH1A1LMNASMN1; SMN2GABRA5L3MBTL1
SCHEMBL286103 0.81 GABRA5 (0.50) ALDH1A1GABRA5L3MBTL1HDAC6HDAC1
SCHEMBL285891 0.79 GABRA5 (0.51) ALDH1A1GABRA5HDAC6HDAC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-B1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN LA ROCHE (CH) 2016-09-28 EP disclosed
US-8178522-B2 Thiazoles HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127974-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286116-A1 THIAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286116-A1 THIAZOLES GABRA5, GABRA1, GABRA4 CACNA1F 288/4885CACNA1D 380/4885CACNA1S 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.